EGFR and non-small cell lung carcinoma: Although the three components Q, L, and K in SAIN can do so by binding to MMP1, MMP3, EGFR, and MET, and are capable of acting as inhibitors by participating in EGFR tyrosine kinase inhibitor resistance, adherens junction, IL-17 signaling pathway, NSCLC, and the relaxin signaling pathway, exerting their functions together to prevent and treat NSCLC (LUAD and LUSC).